Core Viewpoint - The stock of CSPC Pharmaceutical Group (01093) rose nearly 3% towards the end of trading, with a current increase of 2.04%, priced at HKD 7.51, and a trading volume of HKD 408 million [1] Group 1: Clinical Application Approval - CSPC Pharmaceutical's wholly-owned subsidiary, CSPC Ouyi Pharmaceutical Co., Ltd., has had its clinical application for Beipaidu Acid Tablets accepted by the China National Medical Products Administration (NMPA) [1] - Beipaidu Acid is an ATP-citrate lyase inhibitor used to lower low-density lipoprotein cholesterol (LDL-C) in adult patients who cannot tolerate statin therapy, reducing the risk of myocardial infarction and coronary artery revascularization [1] Group 2: Market Potential - Beipaidu Acid was first approved by the FDA in the United States in 2020, and market analysts estimate that it could capture up to 25% of the cholesterol medication market, with peak sales expected to reach between USD 2 billion to USD 3 billion [1] - Currently, no original or generic versions of Beipaidu Acid Tablets have been launched in the domestic market, with four companies, including CSPC Ouyi Pharmaceutical, having their clinical applications accepted, indicating the start of a first-to-market competition [1]
港股异动 | 石药集团(01093)尾盘涨近3% 贝派度酸片临床申请获受理 入局全新“非他汀类”降脂药